| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
DMRA
Damora Therapeutics
|
Jun 15, 2026 | BUY |
Strong Buy
+28.3% avg upside
19 analysts
|
$40.00
88.41% Upside
|
· |
|
SNDX
Syndax Pharmaceuticals
|
Jun 12, 2026 | BUY |
Strong Buy
+88.7% avg upside
27 analysts
|
$31.00
63.24% Upside
|
+0.4% |
|
NUVL
Nuvalent
|
Jun 09, 2026 | HOLD |
Buy
-0.3% avg upside
21 analysts
|
$124.00
0.48% Upside
|
+0.1% |
|
CELC
Celcuity
|
Jun 03, 2026 | BUY |
Strong Buy
+40.6% avg upside
16 analysts
|
$165.00
88.00% Upside
|
-1.0% |
|
OLMA
Olema Pharmaceuticals
|
Jun 01, 2026 | BUY |
Strong Buy
+303.7% avg upside
16 analysts
|
$35.00
268.07% Upside
|
-27.7% |
|
SMMT
Summit Therapeutics
|
Jun 01, 2026 | BUY |
Strong Buy
+112.6% avg upside
27 analysts
|
$40.00
190.84% Upside
|
-11.7% |
|
BCAX
Bicara Therapeutics Inc.
|
May 26, 2026 | BUY |
Strong Buy
+34.2% avg upside
14 analysts
|
$42.00
80.86% Upside
|
+4.3% |
|
RLAY
Relay Therapeutics
|
May 25, 2026 | BUY |
Strong Buy
+26.5% avg upside
19 analysts
|
$26.00
63.75% Upside
|
+11.9% |
|
JANX
Janux Therapeutics Inc
|
May 07, 2026 | BUY |
Strong Buy
+217.9% avg upside
21 analysts
|
$58.00
307.85% Upside
|
-2.7% |
|
ORIC
Oric Pharmaceuticals
|
May 04, 2026 | BUY |
Strong Buy
+180.1% avg upside
19 analysts
|
$18.00
112.08% Upside
|
-14.1% |
|
KYMR
Kymera Therapeutics
|
Apr 30, 2026 | BUY |
Strong Buy
+9.0% avg upside
36 analysts
|
$125.00
38.17% Upside
|
+10.9% |
|
CBIO
Crescent Biopharma
|
Apr 29, 2026 | BUY |
Strong Buy
+26.4% avg upside
17 analysts
|
$35.00
97.76% Upside
|
· |
|
TYRA
Tyra Bioscience
|
Apr 15, 2026 | BUY |
Strong Buy
+57.9% avg upside
17 analysts
|
$54.00
90.75% Upside
|
-16.9% |
|
CGEM
Cullinan Management
|
Mar 10, 2026 | BUY |
Strong Buy
+125.7% avg upside
15 analysts
|
$30.00
99.51% Upside
|
-3.1% |
|
CGON
CG Oncology, Inc.
|
Feb 27, 2026 | BUY |
Strong Buy
+41.1% avg upside
17 analysts
|
$90.00
47.40% Upside
|
+3.9% |
|
CCCC
C4 Therapeutics
|
Feb 26, 2026 | BUY |
Strong Buy
+341.8% avg upside
19 analysts
|
$7.00
68.61% Upside
|
+28.1% |
|
BDTX
Black Diamond Therapeutics
|
Dec 03, 2025 | HOLD |
Strong Buy
+987.8% avg upside
12 analysts
|
— | +2.2% |
|
PYXS
Pyxis Oncology
|
Sep 03, 2025 | BUY |
Strong Buy
+244.6% avg upside
13 analysts
|
$5.00
146.40% Upside
|
+29.2% |
|
KURA
Kura Oncology
|
Sep 03, 2025 | HOLD |
Strong Buy
+162.8% avg upside
26 analysts
|
— | +13.5% |
|
ZNTL
Zentalis Pharmaceuticals
|
Mar 27, 2025 | BUY |
Buy
+295.1% avg upside
16 analysts
|
$9.00
143.25% Upside
|
+17.3% |
|
ALXO
ALX Oncology Holdings
|
Mar 07, 2025 | HOLD |
Strong Buy
+1086.5% avg upside
11 analysts
|
$1.50
2.06% Downside
|
+108.5% |
|
ARVN
Arvinas Holding Company
|
Feb 12, 2025 | BUY |
Buy
+265.4% avg upside
27 analysts
|
$51.00
564.94% Upside
|
-34.0% |
|
AFMDQ
Affimed
|
Jan 09, 2025 | HOLD |
Buy
+12648900.0% avg upside
15 analysts
|
— | · |
|
SRRK
Scholar Rock Holding
|
Apr 26, 2021 | BUY |
Strong Buy
+20.2% avg upside
23 analysts
|
$65.00
37.42% Upside
|
-77.7% |
|
IMA
ImageneBio
|
Apr 26, 2021 | BUY |
Strong Buy
+179.6% avg upside
12 analysts
|
$30.00
399.99% Upside
|
-77.0% |
|
BCAB
BioAtla
|
Apr 26, 2021 | BUY |
Strong Buy
+2580.2% avg upside
13 analysts
|
$68.00
1760.46% Upside
|
-93.7% |
|
GRTX
Galera Therapeutics
|
Apr 26, 2021 | BUY |
Buy
+6826.8% avg upside
7 analysts
|
$15.00
17402.82% Upside
|
· |
|
MGNX
MacroGenics
|
Apr 26, 2021 | BUY |
Buy
+326.4% avg upside
25 analysts
|
$37.00
795.86% Upside
|
-78.5% |
|
EXEL
Exelixis
|
Mar 30, 2021 | BUY |
Strong Buy
-21.1% avg upside
33 analysts
|
$30.00
42.17% Downside
|
+2.1% |
|
ZYME
Zymeworks
|
Mar 30, 2021 | BUY |
Strong Buy
+40.3% avg upside
25 analysts
|
$55.00
137.76% Upside
|
-78.6% |
|
ASMB
Assembly Biosciences
|
Jul 08, 2020 | BUY |
Strong Buy
+38.6% avg upside
10 analysts
|
$38.00
55.48% Upside
|
-85.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.